Screening and Choice of Diagnostic Tests

  • Richard Wender
  • Donald Balaban


Screening healthy patients to detect disease at an early, presymptomatic phase, although not a new idea, has received increasing attention in recent years, and continues to be conceptually appealing to physicians, patients, and society. As the government attempts to limit the costs of medical care, screening activity will be scrutinized more closely by reimbursement agencies; family practitioners therefore face new dilemmas in deciding when, and for whom, a particular test is indicated. This chapter will review the theoretical and practical issues involved in evaluating and selecting screening tests and the criteria used to judge screening programs. It also will review the current recommendations for selecting and conducting screening tests for an urban population.


Iron Deficiency Screen Test American Cancer Society Screen Program Congenital Rubella Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Shapiro S, Strax P, Venet L: Periodic breast cancer screening in reducing mortality from breast cancer. JAMA 215:1777–1785, 1971.PubMedCrossRefGoogle Scholar
  2. 2.
    Vecchio TJ: Predictive value of a single diagnostic test in unselected populations. N Engl J Med 274:1171–1173, 1966.PubMedCrossRefGoogle Scholar
  3. 3.
    McNeil BJ, Adelstein SJ: Determining the value of diagnostic and screening tests. J Nucl Med 17:439–448, 1976.PubMedGoogle Scholar
  4. 4.
    Murphy EA: The Logic of Medicine. Johns Hopkins University Press, Baltimore, 1976.Google Scholar
  5. 5.
    White KL: Contemporary epidemiology. Int J Epidemiol 3:295–303, 1974.PubMedCrossRefGoogle Scholar
  6. 6.
    Fineberg HV, Hiatt HH: Evaluation of medical practices: the case for technology assessment. N Engl J Med 301:1086–1091, 1979.PubMedCrossRefGoogle Scholar
  7. 7.
    Fink DJ: Facts about colorectal cancer detection. Ca-A Cancer J Clin 33:366–367.Google Scholar
  8. 8.
    Veteran’s Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202:1028–1034, 1967.CrossRefGoogle Scholar
  9. 9.
    Veteran’s Administration Cooperative Study Group on Antihytensive Agents: Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 90 through 114 Hg. JAMA 213:1143–1152, 1970.CrossRefGoogle Scholar
  10. 10.
    D’Souza MF, Swan AV, Shannon DJ: A long-term controlled trial of screening for hypertension in general practice. Lancet ii: 1228–1231, 1976.CrossRefGoogle Scholar
  11. 11.
    Weinstein MC, Stason WB: Hypertension: A Policy Perspective. Harvard University Press, Cambridge, Massachusetts, 1976.Google Scholar
  12. 12.
    Crystal RA, Brewster AW: Cost benefit and cost effectiveness analyses in the health field: an introduction. Inquiry 3:3–13, 1966.Google Scholar
  13. 13.
    Canadian Task Force on the Periodic Health Examination: The periodic health examination. CMA J 121:1193–1254, 1979.Google Scholar
  14. 14.
    World Health Organization: Mass Health Examinations. Public Health Paper No. 45, The World Health Organization, Geneva, 1971.Google Scholar
  15. 15.
    Wilson JM, Jungner G: Principles and Practice of Screening for Disease. World Health Organization Press, Geneva, 1968.Google Scholar
  16. 16.
    American Cancer Society: HCS report on the cancer-related check up. Ca-A Cancer Clin 30:194–240, 1980.CrossRefGoogle Scholar
  17. 17.
    Frame PS, Carlson SJ: A critical review of periodic health screening using specific screening criteria, Part 1: selected diseases of respiratory, cardiovascular, and central nervous systems. J Fam Pract 2:29–35, 1975.PubMedGoogle Scholar
  18. 18.
    Frame PS, Carlson SJ: A critical review of periodic health screening using specific screening criteria, Part 2: selected endocrine, metabolic, and gastrointestinal diseases. J Fam Pract 2:123–129, 1975.PubMedGoogle Scholar
  19. 19.
    Frame PS, Carlson SJ: A critical review of periodic health screening using specific screening criteria, Part 3: selected diseases of the genitourinary system. J Fam Pract 2:189–194, 1975.PubMedGoogle Scholar
  20. 20.
    Frame PS, Carlson SJ: A critical review of periodic health screening using specific screening criteria, Part 4: selected miscellaneous diseases. J Fam Pract 2:283–289, 1975.PubMedGoogle Scholar
  21. 21.
    Giagnoni E et al: Prognostic value of exercise EKG testing in asymptomatic normotensive subjects. N Engl J Med 309:1085–1089, 1983.PubMedCrossRefGoogle Scholar
  22. 22.
    Nicklin D, Balaban DJ: Exercise EKG in asymptomatic normotensive subjects (letter). N Engl J Med 310:852–853, 1984.PubMedCrossRefGoogle Scholar
  23. 23.
    Breslow L, Somers AR: The lifetime health-monitoring program: a practical approach to preventive medicine. N Engl J Med 296:601–608, 1977.PubMedCrossRefGoogle Scholar
  24. 24.
    Bush JW, Chen MM, Patrick DL: Analysis of the New York State PKU Screening Program Using a Health Status Index. New York State Health Planning Commission, June, 1973.Google Scholar
  25. 25.
    Eggertsen SC, Schneeweiss R, Bergman JJ: An updated protocol for pediatric health screening. J Fam Pract 10:25–37, 1980.PubMedGoogle Scholar
  26. 26.
    Starfield B, Holtzman NA: A comparison of effectiveness of screening for phenylketonuria in the United States, United Kingdom and Ireland. N Engl J Med 293:118–121, 1975.PubMedCrossRefGoogle Scholar
  27. 27.
    Klein AH, Meltzer S, Kenny FM: Improved prognosis in congenital hypothyroidism treated before age three months. J Pediatr 81:912–915, 1972.PubMedCrossRefGoogle Scholar
  28. 28.
    Oski FA: The nonhematologic manifestations of iron deficiency. Am J Disab Child 133:315–322, 1979.Google Scholar
  29. 29.
    Oski FA, Honig AS, Helu B, Howanitz P: Effect of iron therapy on behavior performance in nonanemic, iron-deficient infants. Pediatrics 71:877–880, 1983.PubMedGoogle Scholar
  30. 30.
    Yip R, Schwartz S, Deinard AS: Screening for iron deficiency with the erythrocyte protoporphyrin test. Pediatrics 72:214–219, 1983.PubMedGoogle Scholar
  31. 31.
    Bailey EN: Screening in pediatric practice. Pediatr Clin North Am 21:123, 1974.PubMedGoogle Scholar
  32. 32.
    Berwick DM, Komaroff AL: Cost effectiveness oflead screening. N Engl J Med 306:1392–1398, 1982.PubMedCrossRefGoogle Scholar
  33. 33.
    Goldberg D, Davidow B: Cost effectiveness of lead screening (letter). N Engl J Med 307:1268, 1982.CrossRefGoogle Scholar
  34. 34.
    Lin-Fu JS: Cost effectiveness of lead screening (letter). N Engl JMed 307:1268–1269, 1982.CrossRefGoogle Scholar
  35. 35.
    Piomelli S: Cost effectiveness of lead screening (letter). N Engl J Med 307:1269, 1982.Google Scholar
  36. 36.
    Kashner TM: Cost effectiveness of lead screening (letter). N Engl J Med 307:1269, 1982.Google Scholar
  37. 37.
    Needleman HL, Frank R: Cost effectiveness of lead screening (letter). N Engl J Med 307:1269–1270, 1982.Google Scholar
  38. 38.
    Froom J, Boisseau V, Sherman A: Selective screening for lead poisoning in an urban teaching practice. J Fam Pract 9:65–70, 1979.PubMedGoogle Scholar
  39. 39.
    North AF: Screening in child health care: where are we now and where are we going? Pediatrics 5:631, 1974.Google Scholar
  40. 40.
    Centers for Disease Control, Atlanta. Morbid Mortal Wkl Rep 33:301–318, 1984.Google Scholar
  41. 41.
    American Society of Health Associations, New York: Today’s V.D. Problem. 1973.Google Scholar
  42. 42.
    Fiumara NJ: Syphilis in newborn children. Clin Obstet Gynecol 18:183–189, 1975.PubMedGoogle Scholar
  43. 43.
    Farquharson R: Antenatal screening for gonorrhea (letter). N Zeal Med J 91:153, 1980.Google Scholar
  44. 44.
    Silverstone PI, Snodgrass CA, Wigfield AS: Value of screening for gonorrhoea in obstetrics and gynaecology. Br J Vener Dis 50:53–56, 1974.PubMedGoogle Scholar
  45. 45.
    Zipursky A: Rh hemolytic disease of the newborn-the disease eradicated by immunology. Clin Obstet Gynecol 20:759–772, 1977.PubMedCrossRefGoogle Scholar
  46. 46.
    Bowman JM: Prevention of haemolytic disease of the newborn. Br J Haematol 19:653–655, 1970.PubMedCrossRefGoogle Scholar
  47. 47.
    Gabbe SG: Diabetes mellitus in pregnancy: have all the problems been solved? Am J Med 70:613–618, 1981.PubMedCrossRefGoogle Scholar
  48. 48.
    Jovanovic L, Druzin M, Peterson CM: Effect of euglycemia on the outcome of pregnancy in insulin-dependent diabetic women as compared with normal control subjects. Am J Med 71:921–926, 1981.PubMedCrossRefGoogle Scholar
  49. 49.
    O’Sullivan JB, Mahan CM, Charles P, Dandrow RV: Screening criteria for high-risk gestational diabetic patients. Am J Obstet Gynecol 116:905, 1973.Google Scholar
  50. 50.
    Carpenter MW, Coustan DR: Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 144:768–773, 1982.PubMedGoogle Scholar
  51. 51.
    Shah BD, Cohen AW, May C, Gabbe SG: Comparison of glycohemoglobin determination and the one-hour oral glucose screen in the identification of gestational diabetes. Am J Obstet Gynecol 144:774–777, 1982.PubMedGoogle Scholar
  52. 52.
    Baker L: Breast cancer detection demonstration project: five year summary report. Ca-A Cancer Clin 32:194–225, 1982.CrossRefGoogle Scholar
  53. 53.
    Gardner JW, Lyon JL: Efficacy of cervical cytologic screening in the control of cervical cancer. Prevent Med 6:487–499, 1977.CrossRefGoogle Scholar
  54. 54.
    Guzick DS: Efficacy of screening for cervical cancer: a review. Am J Pub Health 68:125–134, 1978.CrossRefGoogle Scholar
  55. 55.
    American College of Obstetricians and Gynecologists: The frequency with which cervical-vaginal cytology examination should be performed in gynecologic practice. Tech Bull 29, Chicago, 1975.Google Scholar
  56. 56.
    Winawer SJ, Sherlock P: Surveillance for colorectal cancer in average-risk patients, familial high-risk groups, and patients with adenomas. Cancer 50:2609–2614, 1982.PubMedGoogle Scholar
  57. 57.
    Hardcastle JD, Farrands PA, Balfour TW, Chamberlain J, Amar SS, Sheldon MG: Controlled trial of rectal occult blood testing in the detection of colorectal cancer. Lancet 1:1–4, 1983.CrossRefGoogle Scholar
  58. 58.
    Neuhauser D, Lewicki AM: What do we gain from the sixth stool guaiac? N Engl J Med 293:226–228, 1975.PubMedCrossRefGoogle Scholar
  59. 59.
    Leicester RJ, Pollett WG, Hawley PR, Nicholls RJ: Flexible fibreoptic sigmoidoscopy as an outpatient procedure. Lancet i:34–35, 1982.CrossRefGoogle Scholar
  60. 60.
    Lipshutz GR, Katon RM, McCool MF, Mayer B, Smith FW, Duffy T, Melnyk CS: Flexible sigmoidoscopy as a screening procedure for neoplasia of the colon. Surg Gynecol Obstet 148:19–22, 1979.PubMedGoogle Scholar
  61. 61.
    Haefner DP, Kegeles SS, Kirscht J, Rosenstock IM: Preventive actions in dental disease, tuberculosis, and cancer. Publ Health Rep 82:451–460, 1967.CrossRefGoogle Scholar
  62. 62.
    Rosenstock IM: Prevention of illness and maintenance of health. In: Kosa J, Zola IK (eds). Poverty and Health, A Sociological Analysis. Commonwealth Fund Book, Harvard University Press, Cambridge, Massachusetts, 1975, pp 193–422.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1987

Authors and Affiliations

  • Richard Wender
  • Donald Balaban

There are no affiliations available

Personalised recommendations